We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




VOCs Show Promise for Early Multi-Cancer Detection

By LabMedica International staff writers
Posted on 01 Oct 2025

Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. More...

This makes it difficult to identify tumors across multiple organs at an early stage. Researchers have now demonstrated that chemical “scents” released by the body could serve as reliable markers for detecting cancer earlier and more broadly, providing a foundation for multi-cancer (pan-cancer) screening.

A team of researchers at the Hefei Institutes of Physical Science of the Chinese Academy of Sciences (HFIPS-CAS, Hefei, China) has developed a method that uses volatile organic compounds (VOCs) as potential biomarkers for cancer. For their study, the researchers established a pan-cancer mouse model by chemically inducing tumors in organs such as the lungs, stomach, liver, and esophagus. They then collected urine, feces, and odor samples over a 21-week tumor development period for detailed analysis.

Using headspace solid-phase microextraction gas chromatography-mass spectrometry (HS-SPME-GC-MS), the team performed non-targeted detection of VOCs. The results revealed three sets of tumor-associated compounds that reflected metabolic changes during cancer progression. The study, published in the Journal of Proteome Research, shows that VOCs could effectively distinguish tumor-bearing mice from healthy controls.

Notably, early tumor signals were detectable well before advanced cancer development, appearing in urine at week 5, in odor at week 13, and in feces at week 17. These findings suggest that VOCs can act as early indicators of tumor activity, offering new opportunities for non-invasive screening. The study provides an important experimental framework for applying VOC-based biomarkers in future pan-cancer research.

This approach has the potential to expand screening beyond single cancers, enabling detection across multiple organs simultaneously. If adapted for human use, it could support earlier interventions and reduce reliance on invasive tests, making screening more accessible and effective. Future research will focus on refining VOC detection methods and translating these findings into clinical applications.

Related Links:
HFIPS-CA


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.